Dynamics of Lipid Profile in Antiretroviral-Naive HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study.

ABSTRACT: Background: The introduction of tenofovir alafenamide (TAF) in antiretroviral therapy has deeply modified the choice of the backbone for different treatment regimens, allowing the prevention of the bone and renal toxicity that was related to the previous formulation of tenofovir disoproxil fumarate (TDF). At the same time, literature data show an onset of dyslipidemia after a switch from TDF to TAF. To better understand the possible role of TAF in dyslipidemia, antiretroviral-naïve HIV-infected patients were evaluated, comparing those treated with TAF/emtricitabine with those with abacavir/lamivudine. Methods: We enrolled 270 antiretroviral-naïve HIV-infected patients in an observational, retrospective, longitudinal, multicenter study; they started treatment from 2017 to 2019 and were foll

SUBMITTER: Martini S 

PROVIDER: S-EPMC9775227 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature